Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Deucravacitinib for moderate-to-severe chronic plaque psoriasis
Drug guidance

Deucravacitinib for moderate-to-severe chronic plaque psoriasis

Condition

Skin

Blood and Immune System

17 February 2025

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended deucravacitinib for inclusion on the MOH List of Subsidised Drugs for treating moderate-to-severe chronic plaque psoriasis. The decision was based on the unfavourable clinical and cost effectiveness of deucravacitinib compared with adalimumab, and the unacceptable price-volume agreement proposed by the company.

Deucravacitinib for moderate-to-severe chronic plaque psoriasis (17 Feb 2025) [PDF, 246 KB]

PES Deucravacitinib for treating moderate-to-severe chronic plaque psoriasis (17 Feb 2025) [PDF, 93 KB]

Back to top